Vanguard Group Inc. Grows Stock Position in Humacyte, Inc. (NASDAQ:HUMA)

Vanguard Group Inc. boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 10.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,602,684 shares of the company's stock after buying an additional 543,995 shares during the quarter. Vanguard Group Inc. owned approximately 4.45% of Humacyte worth $28,294,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vontobel Holding Ltd. bought a new stake in shares of Humacyte in the fourth quarter worth about $50,000. Brookstone Capital Management bought a new stake in shares of Humacyte in the 4th quarter worth approximately $56,000. ACT Wealth Management LLC purchased a new position in shares of Humacyte during the fourth quarter valued at approximately $57,000. HighTower Advisors LLC bought a new position in shares of Humacyte during the fourth quarter valued at approximately $66,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Humacyte in the fourth quarter worth $99,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on HUMA. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. Finally, Benchmark restated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $13.71.

Humacyte Stock Up 8.4 %

Shares of NASDAQ HUMA traded up $0.13 on Friday, reaching $1.68. 3,081,887 shares of the company's stock traded hands, compared to its average volume of 3,562,684. The business's 50 day simple moving average is $2.61 and its two-hundred day simple moving average is $4.04. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $9.97. The company has a market cap of $260.60 million, a price-to-earnings ratio of -1.25 and a beta of 1.62.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analysts' expectations of $0.64 million. Analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the firm's stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction dated Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at approximately $62,118. This represents a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock worth $118,224 in the last quarter. Corporate insiders own 11.20% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.